Chapters

Transcript

Video

What was it about the novel, engineered cytokine fusion protein nemvaleukin that led you to revisit the IL-2-mediated therapeutic space in search of a treatment that would overcome previous limitations with high dose human recombinant IL-2?


Created by

CMEducation Resources | iQ&A Cytokine Immunotherapy Intelligence Zone

Presenter

Richard Carvajal, MD

Richard Carvajal, MD

Deputy Physician-in-Chief and Director of Medical OncologyRoy J. and Tara Zuckerberg Professor in Medical OncologyNorthwell Health Cancer InstituteLake Success, NY